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Abstract
Background: The etiology of many cases of childhood-onset chorea remains undetermined, although advances in genomics are revealing both new disease-
associated genes and variant phenotypes associated with known genes.
Methods: We report a Saudi family with a neurodegenerative course dominated by progressive chorea and dementia in whom we performed homozygosity
mapping and whole exome sequencing.
Results: We identified a homozygous missense mutation in GM2A within a prominent block of homozygosity. This mutation is predicted to impair protein function.
Discussion: Although discovered more than two decades ago, to date, only five patients with this rare form of GM2 gangliosidosis have been reported. The
phenotype of previously described GM2A patients has been typified by onset in infancy, profound hypotonia and impaired volitional movement, intractable seizures,
hyperacusis, and a macular cherry red spot. Our findings expand the phenotypic spectrum of GM2A mutation-positive gangliosidosis to include generalized chorea
without macular findings or hyperacusis and highlight how mutations in neurodegenerative disease genes may present in unexpected ways.
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Introduction
As part of an ongoing effort to elucidate the genetic basis of HTT
repeat expansion-negative Huntington-like syndromes, we character-
ized a multiplex, consanguineous Saudi family with chorea, dementia,
and a slowly progressive course. We detected a novel homozygous
mutation in the GM2 activator protein, GM2A, that segregated with
affected status in the family. This familial mutation is associated with a
phenotype distinct from prior reports, which featured earlier-
onset, hyperacusis and cherry red spots and a rapid degenerative
course.
Methods
We enrolled the patients in our ongoing ethics and institutional
review board-approved research studies after written informed consent
had been obtained. The patients were independently ascertained and
reported in table form recently.1 Patient 1, a girl, was born at term
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after an uncomplicated pregnancy (Figure 1A). Her early development
was normal until age 7 years, when she was held back due to severe
anxiety related to the prospect of moving on to the second grade.
Cognitive decline ensued. By age 9 years the patient was only able to
communicate using telegraphic sentences. She developed a pseudo-
bulbar affect. Examinations at school age showed height and weight
below the third centiles with head circumference at the 50th centile.
Neurological examination disclosed mild spastic quadriparesis, limb
dystonia, pyramidal tract signs, and generalized chorea. The patient
exhibited a positive glabellar reflex. Ophthalmological examination
showed no evidence of a cherry red spot. Her startle reactions were
normal. Expressive speech was absent by age 11 years. Her gait
progressively deteriorated and she lost the ability to ambulate at age 12
years as her hyperkinetic disorder gave way to a rigid, akinetic state.
All laboratory investigations were unrevealing. Electroencephalogram
(EEG) was normal. Her magnetic resonance imaging (MRI) showed
mild generalized cerebral atrophy. A muscle biopsy revealed only non-
specific findings. The patient died at age 18 years related to respiratory
tract infection. No post-mortem evaluation was performed.
The patient’s affected sister (patient 2) had a very similar disease
course. Pregnancy, delivery, and early neurodevelopment were
normal. She developed phobias, school avoidance, and intellectual
decline beginning at age 8 years. Height and weight were ,3% but
head circumference was normal. A cherry red spot was conspicuously
absent upon initial funduscopic examination and on repeat examina-
tion at age 18 years. Neurological examination demonstrated mild
scoliosis, a positive glabellar response, and a normoactive startle.
Generalized chorea was present and she developed mild spastic
quadriparesis with limb dystonia; she became progressively hypoki-
netic but retained the ability to ambulate until age 17 years.
Electromyogram and EEG were normal, and MRI showed general-
ized cerebral atrophy.
A male cousin (patient 3) was similarly affected. His birth and
development were normal until age 8 years, when he too demonstrated
multiple phobias. He then developed dysarthria, spasticity affecting his
gait, dystonia, and generalized chorea. He did not show hyperacusis
and no cherry red spot was detected. He lost all expressive speech by
his early teens. Locomotion was preserved until 13 years of age, when
he became dependent on a wheelchair and hypokinetic features began
to dominate his clinical picture (Video 1). MRI demonstrated
generalized cerebral atrophy (Figure 1B). Investigations showed
normal complete blood count with no acanthocytosis and normal
liver and kidney functions.
We initially tested the affected children for HTT CAG numbers by
repeat expansion analysis. Given the family structure (Figure 1A), we
suspected an autosomal recessive disorder with identity by descent.
Homozygosity mapping was performed on patients 1 and 2 and an
unaffected older sister using Affymetrix Whole-Genome 2.7M single
nucleotide polymorphism arrays according to the manufacturer’s
instructions. Whole exome sequencing was performed on patients 1, 2,
Figure 1. Features of Index Family. (A) Pedigree depicting family structure: Circle represent females, squares depict males. Consanguinity is shown via double lines
linking parents. Affected status is denoted by a filled shape. Death is indicated by a slash. (B) Brain magnetic resonance imaging demonstrating generalized cortical atrophy
in patient 3.
Video 1. Patient 3. The patient is shown at age 15 years, with mild residual
chorea, dystonia, and masked facies.
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Table 1. Clinical and genetic features of GM2A-associated disease
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Hex A, Hexosaminidase A; Hex B, Hexosaminidase B; MRI, Magnetic Resonance Imaging.
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and 3 using the Roche/NimbleGen SeqCap EZ V2 capture product
followed by paired-end sequencing using the Illumina HiSeq2000
generating paired-end reads with mean length of 74 bp. Average
coverage depth was .706 with .93% mapped reads, and 12,090,
11,900, and 11,875 homozygous variants detected in patients 1, 2, and
3, respectively.
Results
CAG analysis did not disclose any HTT repeat expansions.
Homozygosity mapping identified two regions of homozygosity .3
Mb in size. Within the larger region (chr5:125,904,993-169,353,466;
43.5 Mb), whole exome sequencing identified a homozygous
c.164C.T (p.P55L) sequence variant in GM2A (ENST00000357164)
with an allele frequency of 0.000825 reported in the ExAc browser.
This change is predicted to be deleterious using SIFT, PolyPhen-2,
and Mutation Taster. This mutation affects a highly conserved proline
within the MD-2-related lipid-recognition domain of GM2A (Figure 2).
The only other variant within the chromosome 5 region of identity by
descent was a homozygous substitution of aspartate for alanine at position
1079 within FAT2. As mutations in this gene have never before been
associated with disease and transcript has been detected only in the
cerebellum,2 this candidate was felt to be unlikely to explain the observed
phenotype, although this possibility cannot be completely excluded.
Mutations in c9orf72, SCA17, VPS13A, HDL2, FXN, RNF216, and PRNP
were not detected, although repeat expansions may evade detection by
short read platforms such as the HiSeq.
Discussion
GM2A encodes for the GM2 activator protein required for the
extraction of lipids from bilayers, lipid solubilization, and presentation
for degradation by hexosaminidase A.3 The mutation we identified is
expected to affect a highly conserved proline that represents the tip of
the hydrophobic region that surrounds the lipid-interacting cup of
GM2A. To date, only five patients with GM2A mutations (GM2 AB
variant; OMIM #272750) have previously been reported.3–7
To our knowledge, this represents the first report of a movement
disorder associated with GM2A mutations, although patients with other
forms of GM2 gangliosidoses (Tay–Sachs or Sandhoff disease) may
present with prominent ataxia,8 dystonia,9 or parkinsonism.10
Hyperkinetic movement disorders are not uncommon in GM2 disease,
although our patients’ prominent chorea was unusual.11 In addition,
our patients lacked the hyperactive startle and macular cherry red
spots that typify early-onset forms of GM2 gangliosidoses, including
those with GM2A mutations (Table 1). Previously reported GM2A
patients demonstrated infantile onset, profound hypotonia, intractable
seizures, and diminished volitional movement. In contrast, our patients
presented at a later age with features that led to a clinical diagnosis of
an HTT-negative Huntington-like syndrome.
Our findings showcase the diverse phenotypes that may be
associated with mutations in neurodegenerative disease genes. As loss
of GM2A function does not affect hexosaminidase A or B activity,
mutations in GM2A may be missed by enzymatic screening methods.
Our results also highlight links between movement disorders and
lysosomal storage diseases as well as the importance of an
unbiased approach to the diagnosis of childhood neurodegenerative
syndromes.
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